266 related articles for article (PubMed ID: 34144133)
1. PLGA-based nanomedicines manufacturing: Technologies overview and challenges in industrial scale-up.
Operti MC; Bernhardt A; Grimm S; Engel A; Figdor CG; Tagit O
Int J Pharm; 2021 Aug; 605():120807. PubMed ID: 34144133
[TBL] [Abstract][Full Text] [Related]
2. Industrial Scale Manufacturing and Downstream Processing of PLGA-Based Nanomedicines Suitable for Fully Continuous Operation.
Operti MC; Bernhardt A; Sincari V; Jager E; Grimm S; Engel A; Hruby M; Figdor CG; Tagit O
Pharmaceutics; 2022 Jan; 14(2):. PubMed ID: 35214009
[TBL] [Abstract][Full Text] [Related]
3. Development and optimization of microfluidic assisted manufacturing process to produce PLGA nanoparticles.
Chiesa E; Bellotti M; Caimi A; Conti B; Dorati R; Conti M; Genta I; Auricchio F
Int J Pharm; 2022 Dec; 629():122368. PubMed ID: 36343906
[TBL] [Abstract][Full Text] [Related]
4. Translating the Manufacture of Immunotherapeutic PLGA Nanoparticles from Lab to Industrial Scale: Process Transfer and In Vitro Testing.
Operti MC; Bernhardt A; Pots J; Sincari V; Jager E; Grimm S; Engel A; Benedikt A; Hrubý M; De Vries IJM; Figdor CG; Tagit O
Pharmaceutics; 2022 Aug; 14(8):. PubMed ID: 36015316
[TBL] [Abstract][Full Text] [Related]
5. Regulatory Considerations, Challenges and Risk-based Approach in Nanomedicine Development.
Csóka I; Ismail R; Jójárt-Laczkovich O; Pallagi E
Curr Med Chem; 2021; 28(36):7461-7476. PubMed ID: 33823761
[TBL] [Abstract][Full Text] [Related]
6. PLGA-Based Nanomedicine: History of Advancement and Development in Clinical Applications of Multiple Diseases.
Alsaab HO; Alharbi FD; Alhibs AS; Alanazi NB; Alshehri BY; Saleh MA; Alshehri FS; Algarni MA; Almugaiteeb T; Uddin MN; Alzhrani RM
Pharmaceutics; 2022 Dec; 14(12):. PubMed ID: 36559223
[TBL] [Abstract][Full Text] [Related]
7. PLGA-based nanoparticles: an overview of biomedical applications.
Danhier F; Ansorena E; Silva JM; Coco R; Le Breton A; Préat V
J Control Release; 2012 Jul; 161(2):505-22. PubMed ID: 22353619
[TBL] [Abstract][Full Text] [Related]
8. Microfluidics for producing poly (lactic-co-glycolic acid)-based pharmaceutical nanoparticles.
Li X; Jiang X
Adv Drug Deliv Rev; 2018 Mar; 128():101-114. PubMed ID: 29277543
[TBL] [Abstract][Full Text] [Related]
9. Translating the fabrication of protein-loaded poly(lactic-co-glycolic acid) nanoparticles from bench to scale-independent production using microfluidics.
Roces CB; Christensen D; Perrie Y
Drug Deliv Transl Res; 2020 Jun; 10(3):582-593. PubMed ID: 31919746
[TBL] [Abstract][Full Text] [Related]
10. Facilitating the translation of nanomedicines to a clinical product: challenges and opportunities.
Agrahari V; Agrahari V
Drug Discov Today; 2018 May; 23(5):974-991. PubMed ID: 29406263
[TBL] [Abstract][Full Text] [Related]
11. PLGA Nanoparticle-Based Formulations to Cross the Blood-Brain Barrier for Drug Delivery: From R&D to cGMP.
Zhi K; Raji B; Nookala AR; Khan MM; Nguyen XH; Sakshi S; Pourmotabbed T; Yallapu MM; Kochat H; Tadrous E; Pernell S; Kumar S
Pharmaceutics; 2021 Apr; 13(4):. PubMed ID: 33917577
[TBL] [Abstract][Full Text] [Related]
12. Translation of nanomedicines from lab to industrial scale synthesis: The case of squalene-adenosine nanoparticles.
Dormont F; Rouquette M; Mahatsekake C; Gobeaux F; Peramo A; Brusini R; Calet S; Testard F; Lepetre-Mouelhi S; Desmaële D; Varna M; Couvreur P
J Control Release; 2019 Aug; 307():302-314. PubMed ID: 31260754
[TBL] [Abstract][Full Text] [Related]
13. Regulatory insights into nanomedicine and gene vaccine innovation: Safety assessment, challenges, and regulatory perspectives.
Souto EB; Blanco-Llamero C; Krambeck K; Kiran NS; Yashaswini C; Postwala H; Severino P; Priefer R; Prajapati BG; Maheshwari R
Acta Biomater; 2024 May; 180():1-17. PubMed ID: 38604468
[TBL] [Abstract][Full Text] [Related]
14. Survey of Clinical Translation of Cancer Nanomedicines-Lessons Learned from Successes and Failures.
He H; Liu L; Morin EE; Liu M; Schwendeman A
Acc Chem Res; 2019 Sep; 52(9):2445-2461. PubMed ID: 31424909
[TBL] [Abstract][Full Text] [Related]
15. Nanomedicines accessible in the market for clinical interventions.
Gadekar V; Borade Y; Kannaujia S; Rajpoot K; Anup N; Tambe V; Kalia K; Tekade RK
J Control Release; 2021 Feb; 330():372-397. PubMed ID: 33370576
[TBL] [Abstract][Full Text] [Related]
16. Advances and challenges in nanocarriers and nanomedicines for veterinary application.
Carvalho SG; Araujo VHS; Dos Santos AM; Duarte JL; Silvestre ALP; Fonseca-Santos B; Villanova JCO; Gremião MPD; Chorilli M
Int J Pharm; 2020 Apr; 580():119214. PubMed ID: 32165220
[TBL] [Abstract][Full Text] [Related]
17. Critical quality attributes in the development of therapeutic nanomedicines toward clinical translation.
Taha MS; Padmakumar S; Singh A; Amiji MM
Drug Deliv Transl Res; 2020 Jun; 10(3):766-790. PubMed ID: 32170656
[TBL] [Abstract][Full Text] [Related]
18. Personalized Nanomedicine: A Revolution at the Nanoscale.
Fornaguera C; García-Celma MJ
J Pers Med; 2017 Oct; 7(4):. PubMed ID: 29023366
[TBL] [Abstract][Full Text] [Related]
19. The effect of autophagy inhibitors on drug delivery using biodegradable polymer nanoparticles in cancer treatment.
Zhang X; Dong Y; Zeng X; Liang X; Li X; Tao W; Chen H; Jiang Y; Mei L; Feng SS
Biomaterials; 2014 Feb; 35(6):1932-43. PubMed ID: 24315578
[TBL] [Abstract][Full Text] [Related]
20. Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status.
van der Meel R; Vehmeijer LJ; Kok RJ; Storm G; van Gaal EV
Adv Drug Deliv Rev; 2013 Oct; 65(10):1284-98. PubMed ID: 24018362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
